Related news from
Fri, 20 Mar 2026 13:25:05 +0000	Here’s Why Cencora (COR) Shares Rose 8% in Q4 TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) in the fourth quarter compared to a -3.70% return for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% […]
Wed, 18 Mar 2026 11:13:35 +0000	1 Healthcare Stock with Exciting Potential and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 3.6% over the past six months, topping the S&P 500 by 2.3 percentage points.
Tue, 17 Mar 2026 17:06:00 +0000	Here's Why You Should Hold Cencora Stock in Your Portfolio for Now Cencora's strong U.S. growth, MSO strategy, and raised outlook support long-term potential, but competition and customer losses remain key risks.
Tue, 17 Mar 2026 12:30:00 +0000	Cencora Announces Financial Leadership Transition CONSHOHOCKEN, Pa., March 17, 2026--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.
Tue, 17 Mar 2026 09:32:18 +0000	Cencora CFO announces retirement James Cleary will step down from the post on June 30, but stay on as an adviser to the company through the end of the year. He’s the second finance chief of a drug distributor to announce their retirement this month.
Fri, 13 Mar 2026 17:07:11 +0000	How Cardinal Health, The IBD Stock Of The Day, Is Navigating The Tricky Macro Cardinal Health is Friday's IBD Stock Of The Day. Shares are in a buy zone as the medical wholesaler easily navigates macro challenges.
Fri, 13 Mar 2026 15:30:05 +0000	Why Is Avantor (AVTR) Down 13.6% Since Last Earnings Report? Avantor (AVTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 13 Mar 2026 13:57:00 +0000	CAH's Pharma Segment Gains 19% in Q2'26: Is the Growth Sustainable? CAH's Pharmaceutical and Specialty Solutions segment surged in fiscal Q2'26 with 19% revenue growth to $61B, fueled by specialty drugs, GLP-1 demand and generics momentum.
Thu, 12 Mar 2026 16:19:00 +0000	Can Specialty Momentum Push CAH's Earnings Growth Beyond 25% in FY26? CAH expects specialty revenues to top $50B in FY26 as its expanding MSO and biopharma services ecosystem helps drive projected EPS growth of 23-26%.
Sun, 08 Mar 2026 02:08:47 +0000	Assessing Cencora (COR) Valuation As Recent Pullback Meets Strong One Year Shareholder Return Cencora (COR) has been drawing attention after recent share price moves, with the stock closing at $358.46. Investors are weighing this level against its recent returns and the company’s large-scale pharmaceutical distribution footprint. See our latest analysis for Cencora. Recent trading has been choppy, with a 1-day share price return of a 0.23% decline and a 7-day share price return of a 3.68% decline, set against a 30-day share price return of 8.63% and a 1-year total shareholder return...
Fri, 06 Mar 2026 16:30:08 +0000	Why Is Cencora (COR) Up 2% Since Last Earnings Report? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 06 Mar 2026 12:26:07 +0000	Is Cencora Stock Outperforming the S&P 500? Due to Cencora's outperformance relative to the broader S&P 500 Index, Wall Street analysts remain strongly optimistic about the stock’s outlook.
Fri, 27 Feb 2026 16:41:25 +0000	Investment Firm Bets Big on ESAB's Welding and Cutting Technology ESAB delivers welding, cutting, and digital solutions to industrial clients worldwide, spanning sectors from construction to energy.
Fri, 27 Feb 2026 15:38:00 +0000	Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced a landmark fulfillment agreement with MWI Animal Health (MWI), part of global healthcare company Cencora, to create the first-ever ultra-low temperature cold chain for veterinary medicine. This comes as Gallant advances toward delivering the potential first-ever FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional approval by the U.S. Food and Drug Admini
Thu, 26 Feb 2026 23:10:48 +0000	Cencora CEO Insider Sale Extends Selling Trend Despite Valuation Upside Cencora (NYSE:COR) President & CEO Robert Mauch recently sold company shares in an insider transaction. The sale extends a year long pattern of insider selling at Cencora, with no disclosed insider share purchases over the same period. The activity comes at a time when investors are closely watching insider moves across the healthcare distribution sector. Cencora, a large pharmaceutical and healthcare products distributor, sits at the center of drug supply chains that link manufacturers,...
Thu, 19 Feb 2026 12:56:00 +0000	COR's MWI Animal Health to Merge With Covetrus in $3.5 Billion Deal Cencora is set to merge MWI Animal Health with Covetrus in a $3.5B deal, retaining a 34.3% stake as it unlocks capital and targets animal health growth.
Wed, 18 Feb 2026 16:18:50 +0000	Top Midday Stories: Palo Alto Networks Shares Fall After Weak EPS Guidance; Meta Partners With Nvidia to Build Hyperscale Data Centers All three major US stock indexes were up in late-morning trading Wednesday ahead of the afternoon re
Wed, 18 Feb 2026 12:17:17 +0000	Cencora's animal health unit to merge with Covetrus in $3.5 billion deal Feb 18 (Reuters) - Drug distributor Cencora will merge its MWI Animal Health with privately held Covetrus in a deal valuing the unit at $3.5 billion, the companies said on Wednesday, creating a
Wed, 18 Feb 2026 12:00:00 +0000	Covetrus and MWI Animal Health to Merge CONSHOHOCKEN, Pa. & PORTLAND, Maine, February 18, 2026--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive agreement under which Covetrus and MWI Animal Health (MWI) will merge, creating a combined company offering a comprehensive animal health platform.
Tue, 17 Feb 2026 13:52:00 +0000	Is the Options Market Predicting a Spike in Cencora Stock? Investors need to pay close attention to COR stock based on the movements in the options market lately.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!